IFP Advisors’s Akari Therapeutics AKTX Stock Holding History

IFP Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.85K	Sell	181 -7,250	-98%	-$62.5K	﹤0.01%	4266
2026 Q1	$1.81K	Buy	+7,431	New	+$69.5K	﹤0.01%	3997
2018 Q2	–	Sell	-1	Closed	-$4K	–	3858
2018 Q1	$4K	Hold	1	–	–	﹤0.01%	3235
2017 Q4	$4K	Buy	+1	New	+$3.86K	﹤0.01%	3284

Other funds holding AKTX

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

IFP Advisors's AKTX Position: Q2 2026 in Review

IFP Advisors reduced its Akari Therapeutics (AKTX) stake by 98% in Q2 2026, selling an estimated $62.5K and leaving 181 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #4266.

IFP Advisors first reported a position in AKTX in Q4 2017 and has held it in 4 quarters since. The position peaked at $4K in Q1 2018. 3 funds tracked by Wall St. Rank hold AKTX as of Q2 2026.

IFP Advisors held 181 shares of Akari Therapeutics worth $1.85K as of Q2 2026.
IFP Advisors sold 7,250 Akari Therapeutics shares in Q2 2026, an estimated $62.5K.
Akari Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4266 holding.
IFP Advisors first reported a position in Akari Therapeutics in Q4 2017 and has held it in 4 quarters since.
IFP Advisors's Akari Therapeutics position peaked at $4K in Q1 2018.
3 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.